Researchers from North Carolina State University have synthesized an analog of lipoxazolidinone A, a small molecule that is effective against drug-resistant bacteria such as MRSA. This molecule, a new synthetic compound inspired by a natural product, could be a useful chemical tool for studying other Gram-positive infections and may have implications for future drug creation.
Lipoxazolidinone A is a natural product which had been previously isolated from bacteria living in marine sediments. It is a secondary metabolite – a small molecule produced by the bacteria that isn’t key to its survival but is produced for a secondary purpose, like defense. When lipoxazolidinone A was initially isolated, researchers noted that it seemed effective against Gram-positive bacteria, like MRSA.
NC State chemist Joshua Pierce aimed to confirm those original findings and understand how the molecule’s structure correlated to its function; in short, he wanted to recreate the molecule to see what portions were directly responsible for its anti-microbial properties and then potentially improve upon that structure.
Pierce, along with current NC State graduate student Kaylib Robinson and former students Jonathan Mills and Troy Zehnder, used novel chemical tools to synthesize lipoxazolidinone A in the lab. They were able to confirm that its chemical structure matched what the initial researchers had indicated, then they worked to identify the portion of the molecule that was responsible for the activity against Gram-positive bacteria. Their result was a compound with improved potency, JJM-35.
They tested JJM-35 against a panel of resistant and non-resistant bacteria. When tested against MRSA in vitro, they found that the synthesized molecule was up to 50 times more effective than the natural product against several bacterial strains. Additionally, they found that the molecule was often more effective against resistant bacterial strains than it was against nonresistant strains.
“An exciting additional aspect of this work was that we identified that these molecules may function by inhibiting multiple biosynthetic pathways directly or indirectly,” says Pierce. “This means that bacteria may have difficulty developing resistance to potential drugs developed from these molecules.”
While more work is needed, Pierce hopes that JJM-35 and similar compounds can be used as tools to study other Gram-positive bacteria and provide a platform for the development of a novel class of anti-infective agents.
“At this point, we have a chemical scaffold – a starting piece of the puzzle. We know that this piece is effective, and so right now all efforts are focused on evaluating the properties of these molecules and their in vivo efficacy,” says Pierce. “The hope is that we can build upon this scaffold to create drugs that are effective against MRSA and other resistant bacteria at a time of dire need for antimicrobial development while also increasing the spectrum of activity.”
The Latest on: Antimicrobial development
via Google News
The Latest on: Antimicrobial development
- Rapid Respiratory Tract Infection Diagnostics – A Test Case?on July 1, 2021 at 11:29 pm
Almost a decade ago the O’Neill Review on Antimicrobial Resistance (AMR) set in motion a process of raising the profile of antimicrobial resistance. The subsequent series of reports published between ...
- From words to action: Exploring the ecosystem of antimicrobial resistanceon July 1, 2021 at 7:45 am
Antimicrobial resistance (AMR) is the ability of microorganisms to evolve to resist antibiotics, leading to infections becoming increasingly untreatable. AMR already claims as many as 33, ...
- The Antimicrobial Resistance Crisis: An Inadvertent, Unfortunate but Nevertheless Informative Experiment in Evolutionary Biologyon June 30, 2021 at 10:03 pm
The global rise of antimicrobial resistance (AMR) phenotypes is an exemplar for rapid evolutionary response. Resistance arises as a consequence of humanity’s widespread and largely indiscriminate use ...
- Arjowiggins launches antimicrobial surface treatmenton June 30, 2021 at 7:59 am
Arjowiggins has launched an antimicrobial surface treatment for paper products that inhibits the ability of bacteria and viruses to survive on the surface.
- The Middle East & Africa Antimicrobial Coatings Market to attain the Fastest Growth Expand with a CAGR of 8% in the Coming Yearson June 29, 2021 at 1:45 am
According to the MarkNtel Advisors research report The Middle East Africa Antimicrobial Coatings Market Analysis 2021 the market shall grow at a CAGR of 8 in the forecast period of 2021 26 The use of ...
- Antimicrobial Suture Market Size to Grow at a CAGR of 13.3% During the Forecast Period 2021-2026on June 28, 2021 at 2:55 pm
Antimicrobial Suture Market” The Increasing Technological Advancements With Research and Development Activities is Driving the Growth of Antimicrobial ...
- Global Antimicrobial Coatings Market Rapidly Changing Covid 19 Pandemic Demand with Capital Analysis Forecast 2021-2027on June 28, 2021 at 6:12 am
The Antimicrobial Coatings market report for the Antimicrobial Coatings market is an assemblage of first hand data along with the quantitative and qualitative valuation and analysis for the forecast ...
- The PASTEUR Act can help win the war against superbugson June 25, 2021 at 7:34 am
A bipartisan bill working its way through the U.S. Congress could go a long way to fighting the deadly problem of antimicrobial resistance.
- Antimicrobial Packaging Market to reach USD 15.48 billion by 2027 - Report by Market Research Future (MRFR)on June 24, 2021 at 4:55 am
Antimicrobial Packaging Market Overview: According to a comprehensive research report by Market Research Future (MRFR), “Antimicrobial Packaging Market Research Report, Material, Type, Application and ...
via Bing News